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Abstract. Depression and anxiety are the most common mood disorders affecting 300 million sufferers worldwide. Maladap-
tive changes in the neuroendocrine stress response is cited as the most common underlying cause, though how the circuits
underlying this response are controlled at the molecular level, remains largely unknown. Approximately 40% of patients do
not respond to current treatments, indicating that untapped mechanisms exist. Here we review recent evidence implicating
JNK in the control of anxiety and depressive-like behavior with a particular focus on its action in immature granule cells of
the hippocampal neurogenic niche and the potential for therapeutic targeting for affective disorders.
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Anxiety and depression are among the largest
causes of disability worldwide [1]. They have com-
plex and varied etiologies with genetic, epigenetic
and environmental factors contributing to disease sus-
ceptibility. Maladaptative changes in normal stress
responses leading to long lasting physical changes
at the level of synapses and circuits are believed
to be among the underlying causes. Antidepres-
sant drugs have targeted the same core mechanisms
for several decades, yet treatment-resistant depres-
sion is still a major problem, indicating the need
for a paradigm shift [2]. Many theories of depres-
sion have been proposed, including dysregulation
of monoaminergic neurotransmission, neurotrophic
factors and hippocampal neurogenesis [3, 4]. How-
ever, the signalling molecules that govern mood and
its underlying circuitry are largely unknown and iden-
tifying these will be essential for a comprehensive
understanding of mood disorders and development
of new treatments.
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ADULT HIPPOCAMPAL NEUROGENESIS
AND DEPRESSION
Prominent studies have shown that adult hip-
pocampal neurogenesis is required for the action of
antidepressant drugs [5–8], as well as for electrocon-
vulsive shock therapy [9]. This discovery prompted
extensive studies of adult born hippocampal granule
cells in the context of mood, leading to the hypothesis
that depressive and anxiety symptoms can be allevi-
ated by boosting neurogenesis in the hippocampus
while impaired neurogenesis may be causal in trig-
gering symptoms initially. Yet, this theory remains
controversial as other studies have shown beneficial
effects of antidepressants that were independent of
neurogenesis changes [10, 11]. Our lab identified that
inhibition of c-Jun N-terminal kinase (JNK) in the
hippocampal neurogenic niche increases the number
of adult born granule cells, while alleviating anxi-
ety behaviour [12]. More critically, we demonstrated
that inhibiting JNK solely in adult born granule cells
was sufficient to alleviate anxiety and depressive
behavior [12]. These findings implicate JNK as a cen-
tral player that controls anxiety and depression from
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a subpopulation of adult born granule cells in the
hippocampus.
First described in the hippocampus [13], the gener-
ation of new neurons in adult brain, or “neurogenesis”
occurs at a rate of about 700 new granule cells
added daily per hippocampus in humans, represent-
ing 0.004% of dentate gyrus neurons [14]. Notably,
adult hippocampal neurogenesis is confined to the
dentate gyrus sub-region of the hippocampus in all
species [15]. In rodents, the extent of neurogenesis
in the dentate gyrus is higher [16], accounting for up
to 0.06% of dentate gyrus granule cells in two month
old mice [17, 18]. Increased neurogenesis in the dor-
sal hippocampus has been shown to improve spatial
memory [19, 20] whereas in the ventral hippocam-
pus, it is associated with suppression of anxiety-like
behaviour [7, 21–23]. Neurogenesis in mice can be
boosted by exercise or by exposure to an enriched
environment [17, 22, 24], leading to improved mem-
ory [25, 26]. However, running induces neurogenesis
in the dorsal and not the ventral hippocampus [27],
and running-induced suppression of anxiety has
been dissociated from hippocampal neurogenesis
[7, 10, 11, 28].
ANXIETY AND DEPRESSION – THE
HIPPOCAMPAL CONNECTION
Anxiety is a normal stress response that allows
the individual to react to a threatening environment.
Anxiety disorders arise when this stress response
occurs in the absence of real threat. It shows a high
level of comorbidity with depression and rates of
secondary depression following a prior psychiatric
illness, in particular anxiety, have grown signifi-
cantly in modern times [29]. In depressed individuals,
disease-associated structural changes take place in
the hippocampus, indicating a central role for this
region in the underlying pathology. Neuroimaging
studies have suggested that hippocampal volume may
be reduced in patients suffering from depression and
anxiety [30, 31]. These findings from small patient
cohorts have been validated by meta-analysis (involv-
ing 1728 major depressive disorder (MDD) patients
and 7199 controls) and conclude that hippocampal
volume decreases on average by 1.42% in MDD.
Moreover, this decrease in hippocampal volume cor-
relates with recurrence frequency [31]. Post-mortem
studies in MDD subjects revealed loss of neuropil,
i.e. neuritic matter consisting of unmyelinated axons,
dendrites or glial cell processes, suggesting that
neurite atrophy and synapse loss accounted for dimin-
ished volume in this region [32, 33]. Specifically in
the hippocampal Cornu Ammonis-3 (CA3) region,
reduced dendrite and spine density was associated
with higher levels of trait anxiety and longitudinal
depression scores [34, 35], while in the dentate gyrus
sub-region, the number of neural progenitor cells and
granule cells was reduced in MDD subjects [36, 37].
While these anatomical hallmarks of MDD suggest
that levels of adult hippocampal neurogenesis may
be reduced in these individuals, definitive proof that
neurogenesis is impaired in humans suffering from
affective disorders is still lacking. This is because
no studies have used birth dating approaches to study
neurogenesis in post mortem brains from humans that
suffered from these disorders. Also, there are cur-
rently no methods to directly measure neurogenesis
in situ in humans.
Stereological measurement of neurogenesis in
post mortem brain has provided some evidence for
a link between depression and adult hippocampal
neurogenesis. For example, depressed subjects that
received selective serotonin reuptake inhibitor (SSRI)
or tricyclic anti-depressant (TCA) drugs, showed
increased neural progenitor number in the anterior
(ventral) dentate gyrus compared to untreated sub-
jects [36]. Another study showed that hippocampal
volume was restored in patients that received antide-
pressant drugs [37]. Interestingly, the meta-analysis
found no significant recovery of hippocampal vol-
ume in patients undergoing antidepressant treatment
[31], possibly due to confounding interactions such as
severity and duration of disease. Nonetheless, these
clinical studies have provided clear evidence that
structural changes occur at many levels in the hip-
pocampus of individuals suffering from depression
and anxiety and have given insight into the underlying
pathology.
Similarly in animal models, the hippocampus
emerges as a central regulator of depression and
anxiety [38–42]. The ventral hippocampus extends
connections to prefrontal cortex (PFC) [43] and
forms reciprocal connections with amygdala [41],
among other regions [44–46]. These circuits are
highly conserved and are required for synchronized
hippocampal-PFC activity and normal adaptive, anx-
iety behaviour [47]. Maladaptive changes in circuits
emanating from the hippocampus are likely to con-
tribute to the pathological state where anxiety is
present in the absence of threat [48]. The signalling
molecules driving these circuits and maladaptive
changes therein are largely unknown.
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C-JUN N-TERMINAL KINASES (JNKS)
JNK was originally identified as stress-activated
protein kinase (SAPK) that responded to a range of
cellular stressors including DNA damage, oxidative
stress, cytoskeletal toxins, infection and inflamma-
tion [49]. SAPK was renamed “JNK” when it was
identified as the kinase responsible for phosphoryla-
tion and transcriptional activation of c-Jun [50, 51].
In brain, JNK expression is complex, with three JNK
genes; JNK1 (MAPK8), JNK2 (MAPK9) and JNK3
(MAPK10)and10splicevariants (JNK11, JNK12,
JNK11, JNK12, JNK21, JNK22, JNK21,
JNK22, JNK31, JNK32) being expressed [52].
JNKs are associated with inflammation, neurode-
generation and insulin resistance [53–55]. JNKs are
particularly important kinases in brain where they
display elevated activity in the absence of stress, indi-
cating that brain JNKs also serve non-stress related
functions. This distinguishes brain JNK from JNK
in other tissues such as heart, lung, kidney, spleen
and liver, where its activity is low in the absence
of stress [56]. JNK1 constitutes a major compo-
nent of physiologically active JNK in brain, whereas
JNK2 and JNK3 isoforms exhibit lower basal activity
and increased stress responsivity [57]. Yet, knock-
out or knockdown of all three JNK isoforms has
been necessary to reveal functions for JNK in trophic
deprivation-induced neuronal death [58], autophagy
[59] and pituitary function [54] indicating functional
redundancy between isoforms. JNK has also been
shown to regulate neuropathic pain [60] and inhibition
of JNK protects from neuronal death following cere-
bral ischemia [61, 62]. Interestingly however, with
the exception of JNK regulation of pituitary function
and insulin resistance [63, 64], until recently, there
was relatively little known about the physiological
role of JNK in adult brain based on in vivo study and
behavioural analysis. Here we outline recent evidence
that associates JNK with the control of mood.
JNK1 REGULATES ANXIETY AND
DEPRESSIVE-LIKE BEHAVIOUR IN MICE
To gain insight on JNK1 function in adult brain,
Jnk1-/-miceweresubjected toabatteryofbehavioural
tests. The most prominent results emerged from tests
for anxiety where Jnk1-/- mice displayed a low anx-
iety phenotype in the open field, elevated plus maze
and light-dark tests [12] (Table 1). In the forced swim
test of behavioural despair and the sucrose deprivation
test to determine anhedonic behaviour, Jnk1-/- mice
displayed reduced immobility and reduced anhedonia
respectively, indicating a low depressive phenotype
[12] (Table 1). These behavioural phenotypes were
replicated when mice underwent intracerebroventric-
ular infusion for six weeks with a peptide inhibitor
of JNK (DJNKI-1, chemically identical to XG-102)
(Fig. 1A; Table 1) [12].
JNK1 ACTIVITY IN NEWBORN
GRANULE CELLS OF THE
HIPPOCAMPUS INDUCES ANXIOGENIC
AND DEPRESSIVE BEHAVIOR
Changes in the rate of adult hippocampal neuroge-
nesis have been implicated in the pathology of anxiety
and depression [3, 65]. We therefore examined neu-
rogenesis in Jnk1 knockout mice using birthdate
labelling. These results showed that progenitor cell
proliferation was increased in the dentate gyrus of
mice lacking Jnk1 and that the number of adult
born (BrdU/NeuN-positive) neurons was increased
(Fig. 1B) [12]. Moreover, cell survival and den-
drite maturation, as measured by arborisation, was
elevated in Jnk1 knockout mice (Fig. 1B) [12]. Impor-
tantly, these effects were replicated upon mini-pump
infusion to the ventricles with a peptide inhibitor
of JNK1 for six weeks (Fig. 1B) [12]. Finally, to
determine whether adult born granule cells them-
selves were involved in the anxiolytic response, we
expressed the JNK inhibitor in a Murine Leukemia
Virus (MLV) plasmid and injected it to the hilus.
This enabled selective targeting of the JNK inhibitor
to newly born granule cells in the hippocampus of
adult mice [12]. To our surprise, JNK inhibition solely
in these cells was sufficient to reduce anxiety and
depressive behaviour, indicating that JNK activity in
newborn granule cells of the hippocampus plays an
important role in the regulation of mood. Notably,
there was no increase in granule cell number in these
mice. Thus, like others [10, 11], we showed that
increased neurogenesis was not necessary for this
behavioural switch, as inhibition of JNK in new born
granule cells was sufficient to improve mood in mice
without having any effect on number of immature
granule cells (Fig. 1B) [12].
THE DJNKI-1 INHIBITOR OF JNK
To inhibit JNK, the peptide inhibitor of JNK,
DJNKI-1 (also known as XG-102) was used. This
148 P. Hollos et al. / JNK Regulation of Depression and Anxiety
is the minimal sequence from the JNK scaffold,
JNK interacting protein-1 (JIP1) that binds to the
common docking domain of JNK and competes for
substrate binding [53, 66]. DJNKI-1 also encodes
the transactivator of transcription (TAT) sequence
from the HIV vector which facilitates cell penetration
[67, 68]. Further, to improve resilience against enzy-
matic digestion in vivo, DJNKI-1 utilizes D-amino
acids, providing stability in cells for at least two
weeks [69]. DJNKI-1 is considered to be a specific
inhibitor of JNK and does not inhibit the closely
related ERK or p38 kinases [70]. In our hands,
DJNKI-1 more potently inhibits JNK1 isoforms over
JNK2 and JNK3 in vitro (Coffey lab unpublished
data), however its bioactivity against JNK isoforms
in vivo has not been characterised. For this reason,
it is significant that we cross-validated the findings
with DJNKI-1 in Jnk1-/- mice.
Our lab has earlier shown that a longer version of
the JNK inhibitor peptide, amino acids 1–277 of the
JNK scaffold JIP1 (JBD for JNK binding domain),
increased dendrite arborisation in cultured neurons,
recapitulating findings in Jnk1-/- mice where den-
drite arborisation was increased in the cerebellum
and motor cortex [71, 72]. Thus, it was not alto-
gether surprising that in adult hippocampus, JNK1
constrained the arborisation of doublecortin (DCX)-
positive, immature granule cells (Fig. 1B) [12].
Indeed inhibition of JNK1 proved to be a pow-
erful stimulus for adult hippocampal neurogenesis,
promoting all four stages: proliferation, survival,
differentiation and maturation (Fig. 1B).
HOW COULD JNK INHIBITION IN
GRANULE CELLS ALTER BEHAVIOUR?
Dentate gyrus granule cells form a major cell group
of the hippocampal trisynaptic circuit. They receive
excitatory input from the entorhinal cortex via per-
forant path axons and transmit this to CA3 pyramidal
neurons via their mossy fibers. The circuit is com-
pletedbyprojections fromCA3toCA1whichprojects
back to the entorhinal cortex. Indeed, the immature
granule cells of the hippocampus are particularly sen-
sitive toperforantpath input [73].Theydisplaya lower
activation threshold than resident granule cells due to
their particular configuration that equips them with
increased excitatory/inhibitory balance [73]. Signif-
icantly, immature granule cells negatively regulate
the overall activity of resident dentate granule cells
by recruiting local GABAergic inhibitory neurons
[42, 73, 74]. Consistent with this, increasing neu-
rogenesis in mice leads to reduced activity of the
dentate gyrus hippocampal subregion [42, 74, 75].
Conversely, blocking neurogenesis using x-ray irra-
diation or chemical genetic ablation, increases dentate
gyrus gamma burst amplitude and synchronized firing
[76]. The ventral hippocampus forms direct monosy-
naptic connections to structures that regulate mood
such as medial prefrontal cortex which promotes anx-
iety behaviour [47, 77], reciprocal connections to and
from amygdala, which governs fear processing [78],
and to the medial shell of the nucleus accumbens [79,
80] which controls reward seeking behaviour and sus-
ceptibility to stress [81]. Thus boosting the number of
adult born granule cells, or increasing their activity, is
expected to reduce the neural activity of glutamatergic
projections from the ventral hippocampus to down-
stream structures that regulate anxiety and reward
responses [42]. Indeed, it has recently been shown
that excitatory output from the ventral hippocampus
to the medial prefrontal cortex is required for anxious
behavior [47], while reduced activity in this region is
associated with stress resilience in the chronic social
defeat model of depression [81]. One possibility is
that JNK evokes anxiogenic behaviour by control-
ling properties of immature granule cells leading to
Table 1
Inhibition of JNK1 lowers anxiety and depressive behaviour in mice
Jnk1-/- DJNKI-1 (XG-102) MLV-NLS-JBD
2–4 months 2–4 months 2–4 months
Behavioraltests Anxiety/depressivephenotype
EPM ↓ ↓ ↓
Light/Dark ↓ ↓ ↓
Open Field ↓ n.a. ↓
FST ↓ ↓ ↓
Anhedonia ↓ ↓ ↓
Summary of behavioural test results from Mohammad and colleagues [12]. DJNKI-1 refers to a peptide inhibitor
of JNK, also known as XG-102. MLV-NLS-JBD encodes amino acids 1 to 277 of JIP1 in a MLV retroviral vector
with upstream flanking nuclear localisation sequences (NLS). The JBD sequence effectively inhibits nuclear JNK
in neurons [71, 107].
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Fig. 1. Inhibition of JNK solely in newborn granule cells of the hippocampus alleviates anxiety and depressive behaviour whereas global
inhibition of JNK1 in brain boosts neurogenesis. A. Genetic ablation of Jnk1, intracerebroventricular (ICV) osmotic mini-pump infusion of
DJNKI-1 (XG-102) over six weeks, or retroviral delivery of JNK inhibitor (MLV-NLS-JBD) to granule cells of the dentate gyrus for six weeks,
evoke an anxiolytic and anti-depressant effect. The key finding was that specific targeting of adult born granule cell JNK was sufficient to
switch behaviour to a low anxiety and low depressive state independent of neurogenesis changes [12]. B. Levels of neurogenesis were assessed
in Jnk1-/- mice or DJNKI-1-treated mice. Neurogenesis was increased at several levels. There was increased proliferation (BrdU cell number,
Ki67-positive cells), survival (decreased numbers of cells positive for cleaved caspase-3) and increased numbers of doublecortin (DCX)-
positive and BrdU/NeuN-positive cells, representing newly born neurons. Thus global JNK1 inhibition increases hippocampal neurogenesis.
However inhibition of JNK solely in immature granule cells using retroviral delivery alleviates mood without increasing neurogenesis, telling
us that JNK inhibition evokes separable effects in the hippocampal neurogenic niche, both of which act to lower anxiety and depression.
increasedventralhippocampaloutput, thoughthis the-
ory requires testing.
From the molecular standpoint, there are sev-
eral mechanisms whereby JNK could influence the
behaviour of new born granule cells leading to
changes in the activity of circuits that control mood.
New born granule cells exhibit specialized features
during a “critical period” from two to six weeks
after birth [73]. Within this timeframe, new gran-
ule cells show a lower threshold for activation by
perforant-path excitatory hippocampal input. This
distinguishes them from the resident mature cells
that account for ∼90% of dentate neurons and are
less easily excited [73, 82]. Increased excitability
of immature granule cells is dependent on high
expression during the critical period, of the NKCC1
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cotransporter which carries Cl− inwards. High
expression of NKCC1 (SLC12A2) results in reversal
of the Cl– potential, meaning that upon GABA-
A receptor activation, Cl– flows outwards, down
its concentration gradient and the neurons become
depolarized, rather than hyperpolarized [82]. As
these neurons mature, NKCC2 (SCL12A1) expres-
sion increases and internal Cl– concentrations are
restored to lower levels. At this point, granule
cells display typical GABA-A responses, i.e. Cl–
ions are driven outwards leading to hypolarization
[83, 84]. JNK has been shown to phosphorylate
NKCC1 in vitro in [85], however whether this alters
the activity or expression levels of the cotransporter
is not known.
Other key changes that occur to immature gran-
ule cells during the critical period include dendritic
arborisation and spine formation, together represent-
ing increased capacity for synaptic integration. In this
regard, we have shown that dendritic field size is
increased in immature granule cells in Jnk1-/- or JNK
inhibitor-treated mice [12]. NMDA receptor NR2B
subunit expression is also increased during this period
and facilitates synaptic plasticity [86]. Whether JNK
controls NR2B expression is not known. All in
all one can envisage several possible mechanisms
whereby pathological activation of JNK (as outlined
in Table 1) could alter properties of immature granule
cells, either indirectly by altering gene expression, or
directly by switching on or off protein function. More
precise understanding of what JNK does in immature
granule cells to alter mood will be greatly facilitated
by phosphoproteomic study and analysis of circuits
and gene expression.
WHAT IS KNOWN ABOUT JNK
REGULATION IN ANIMAL MODELS OF
DEPRESSION?
Studies in animal models of depression have shown
that JNK activity is elevated in the hippocampus and
prefrontal cortex (Table 2) [87–93]. For example,
chronic treatment with corticosterone [94], strongly
activates JNK in the hippocampus [93]. Elevated
levels of cortisol in depression signifies impaired
feedback regulation of the hypothalamic pituitary
adrenal axis [95] and contributes to long lasting
synapse loss [35]. Similarly, in chronic variable stress
models of depression and in acute stress models (cold
followed by rewarming) [87], forced swim and tail
suspension tests [91] and immobilization stress [88],
JNK is hyper-activated in the hippocampus and pre-
frontal cortex (Table 2). Significantly, in the social
defeat stress model of depression, JNK activity is
increased in animals that are susceptible to stress and
reduced in animals that are resilient [90], suggesting
Table 2
Regulation of JNK activity in rodent models of depression
STRESSOR OR DISEASE MODEL JNK ACTIVITY BEHAVIOR CORT REFERENCES
CHRONIC STRESS
Corticosterone 40 day (mice) ↑↑ HC Cognitive deficit reversed n.a. [93]
by DJNKI-1
Random varied (mice) ↑ HC n.a. ↑ [89]
Random varied + LPS ↑↑ HC
Social defeat (mice) ↑ PFC susceptible mice ↑ Social avoidance n.a. [90]
↓ PFC resilient mice ↓ Social avoidance
SOCIAL ISOLATION
Social isolation 21 day (rat) ↓ PFC n.a. No change [92]
Social isolation 21 day + acute ↓ PFC n.a. ↑
immobilization
Social isolation 21 day (rat) ↓ HC/PFC n.a. ↑ [88]
ACUTE STRESS
Cold (mice) No effect HC/PFC Anxiogenic ↑ [87]
Cold/rewarming ↑↑ HC/PFC/EC ↑
Forced swim No effect HC, ↑ PFC Depressive n.a. [91]
Tail suspension ↑ HC/PFC Depressive
Cold (rat) No effect n.a. ↑ [92]
Immobilization No effect n.a. ↑
Immobilization (rat) ↑↑ HC/PFC n.a. ↑ [88]
LPS ↑ HC n.a. ↑ [89]
In these studies, JNK activity was measured by immunoblotting hippocampus (HC) or prefrontal cortex (PFC) with antibodies detecting
active JNK (P-JNK). Chronic and acute stress models are categorized separately. Abbreviations are as follows: Lipopolysaccharide = LPS,
Corticosterone = CORT, data not available = n.a.
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that JNK activity predisposes to depression and inhi-
bition of JNK is protective. In contrast to these
classic models of depression, exposure of adult rats
to 21 days of social isolation (a model for depres-
sion and negative symptoms of schizophrenia [96]),
does not activate JNK but slightly decreases its activ-
ity in the hippocampus and PFC [88, 92] (Table 2).
While the stress response was validated in these
two studies by showing increased corticosterone lev-
els, the behavioural outcome was not monitored.
The reported decrease in JNK activity may there-
fore represent a protective, adaptive response to
social isolation in this relatively short duration iso-
lation model. Finally, cognitive impairment induced
by chronic corticosterone administration is reversed
by the DJNKI-1 inhibitor [93], while DJNKI-1 also
lowers baseline anxiety and depressive behaviour
[12]. Together these data provide evidence that
JNK is activated in rodent models of depression
and that preventing this activation alleviates anxiety
and depressive behaviour. Significantly also, reduced
JNK activity is associated with resilience to stress.
Genetic components together with environmental
influences also contribute to depression and predis-
posing gene anomalies are actively searched [97].
As of now, no significant genome-wide associations
have been found to link the JNK pathway with
MDD or bipolar disorder. Although SNPs in the
JIP2 (MAPK8IP2) JNK scaffold [98] and in JNK3
(MAPK10) [99] were identified in patient cohorts,
these have not shown significant genome-wide asso-
ciations. Such associations may be obscured by the
heterogenous nature of the disease etiology. The first
genetic associations with depression are only start-
ing to be identified and improved patient stratification
and larger sample sizes will be needed to achieve a
comprehensive picture of the genetic background of
depression [100].
TARGETING JNK FOR DEPRESSION AND
ANXIETY?
These findings from animal studies, highlight the
possibility that targeting of the JNK pathway could
provide a new avenue for tackling depression and
anxiety. It may even provide benefit for treatment
resistant depression. This raises the question as to
whether unwanted side effects would be associated
with systemic inhibition of JNK. JNKs, by virtue of
being kinases, are involved in a variety of functions
[55]. Inhibition of JNK is expected to be beneficial
for several diseases including cancer, inflammatory
diseases, diabetes, neurodegenerative disease, stroke
[53], and more recently, depression and anxiety [12,
90]. Indeed, because JNKs are largely silent and acti-
vated by stress, there is a rationale to expect minimal
side effects. However, cellular stress responses also
serve important homeostatic functions. For example
JNKs regulate autophagy, albeit oppositely in the
periphery and CNS [59, 101]. Also, JNKs 1 and 2
are required for innate immune response signalling
[102], and as discussed earlier, JNK isoforms play
essential roles during brain development [55]. One
can predict therefore that pan-JNK inhibitors would
be precluded from use. However, because these
important functions of JNKs are largely redundant
between isoforms, it is anticipated that isoform-
specific inhibitors, or inhibitors of specific functional
modules, could be tolerated. Several years of drug
development have generated a number of inhibitors
against JNK, however a full panel of isoform-specific,
or splice variant-specific inhibitors is not yet avail-
able [103]. In terms of tolerance, two clinical trials
with small molecule ATP-competitive JNK inhibitors
have been carried out [103, 104]. These were ter-
minated due to a poor risk/benefit ratio, however
these trials did not stratify patients, and it has been
proposed that isoform-specific JNK inhibitors would
have produced a better outcome [104]. Interestingly
however, a small cohort safety trial using DJNKI-1
(XG-102, Brimapitide) reported no drug-related side
effects following a single intravenous infusion [105].
Moreover, this inhibitor yielded positive results in
the postoperative treatment of ocular inflammation
[106], where a single injection showed similar ben-
efit to four applications of dexamethasone over 21
days. This inhibitor is currently undergoing preclini-
cal study for treatment of Alzheimer’s disease. Given
the recent implications of JNK involvement in depres-
sion, it would certainly be of interest to monitor the
effects of JNK inhibition on depression and anxiety
symptoms in patients, if such trials go ahead.
CONCLUSIONS
This review highlights recent data that implicates
the JNK pathway in the regulation of mood. These
early findings are exciting for the following rea-
sons. Firstly, according to current knowledge, there is
no overt connection between JNK and the currently
used anti-depressant drugs. Therefore, targeting of
this mechanism may represent a new avenue for
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treatment development. Secondly, the precise local-
ization of JNK’s anxiogenic action to the immature
granule cells of the hippocampus provides the pos-
sibility for design of selective targeting approaches.
In this regard, it will be advantageous to understand
more aspects of JNK action in adult born granule cells
from in vivo study. While much remains to be under-
stood, we can say that JNK has entered the arena as a
kinase that controls anxiety and depressive behaviour
in mice, and may contribute to maladaptive changes
underlying affective disorders.
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